Replies to post #392443 on Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Or that Redesiver failed it's first trial but with more testing went on to be the standard of care. Through the NIH Brilacidin is also getting further testing. Likely even much further.

[sunspotter]

“ Bril is more of a prevention.”

Even if that were true - which no one knows- then a 5 day IV regimen is somewhat impractical for prophylaxis.

To say the least.

[sunspotter]

“you never mention the Heparin effect on Brilicidin, why is that?”

Because as I have mentioned many times, I suspect the key to brilacidin’s efficacy in vitro and its ineffectiveness in vivo is due to phospholipidosis, not heparin.

Anyway, most COVID-19 patients will get heparin anyway, so even if thast's why brilacidin failed (it isn't acording to IPIX' own assessment) then it would still mean it has extremely limited clinical utility.

The fact is that only 7% of the moderate-to-severe COVID-19 patients in the study died, whether they were on brilacidin or not.

So hurray for standard of care!